Phase II Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy

Date Added
November 15th, 2016
PRO Number
Pro00059559
Researcher
Michael Lilly

List of Studies


Keywords
Cancer/Genitourinary
Summary

The purpose of this study is to identify a safe pharmaceutical agent that can reduce the AGE levels in subjects with advanced cancer. The term "AGE" (advanced glycation endpoints) refers to sugar-derived metabolites that are linked to lifestyle choices and can contribute to cancer.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-cto-clinops@musc.edu



-- OR --